ABSTRACT
Mucormycosis is a fungal infection which is caused by a rare type of opportunistic fungal pathogen called mucormycetes. It is a serious and potentially fatal fungal infection. A wide range of bacterial and fungal co-infections have been associated with COVID 19. The second wave of COVID 19 showed a sudden surge in mucormycosis. The most commonly observed form was rhino cerebral mucormycosis. Most of the patients had diabetes as a pre-disposing factor and had received steroids, oxygen therapy, biologicals and antibiotics as a part of treatment of COVID 19. COVID 19 in itself favours the growth of mucormycosis owing to the weakened immune system. While the diagnosis of mucormycosis still remains challenging the treatment mainly aims at managing co-morbid condition in high-risk group, anti-fungal therapy using Amphotericin B and azoles and surgical debridement. In this article, we analysed, 71, histopathologically confirmed cases of mucormycosis associated with COVID 19 admitted and studied their clinical profile and risk factors associated with it.